10 research outputs found
Recommended from our members
A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease.
Novel coronavirus disease 2019 (COVID-19) is a highly infectious, rapidly spreading viral disease with an alarming case fatality rate up to 5%. The risk factors for severe presentations are concentrated in patients with chronic kidney disease, particularly patients with end-stage renal disease (ESRD) who are dialysis dependent. We report the first US case of a 56-year-old nondiabetic male with ESRD secondary to IgA nephropathy undergoing thrice-weekly maintenance hemodialysis for 3 years, who developed COVID-19 infection. He has hypertension controlled with angiotensin receptor blocker losartan 100 mg/day and coronary artery disease status-post stent placement. During the first 5 days of his febrile disease, he presented to an urgent care, 3 emergency rooms, 1 cardiology clinic, and 2 dialysis centers in California and Utah. During this interval, he reported nausea, vomiting, diarrhea, and low-grade fevers but was not suspected of COVID-19 infection until he developed respiratory symptoms and was admitted to the hospital. Imaging studies upon admission were consistent with bilateral interstitial pneumonia. He was placed in droplet-eye precautions while awaiting COVID-19 test results. Within the first 24 h, he deteriorated quickly and developed acute respiratory distress syndrome (ARDS), requiring intubation and increasing respiratory support. Losartan was withheld due to hypotension and septic shock. COVID-19 was reported positive on hospital day 3. He remained in critical condition being treated with hydroxychloroquine and tocilizumab in addition to the standard medical management for septic shock and ARDS. Our case is unique in its atypical initial presentation and highlights the importance of early testing
The Student Movement Volume 106 Issue 8: Cardinals Cheer, Thanksgiving is Here!
HUMANS
Meet Your 2021-2022 AU Cardinals Men\u27s Basketball Team, Interviewed by: Timmy Duado
What Are You Thankful For?, Interviewed by: Grace No
Meet Your 2021-2022 AU Cardinals Women\u27s Basketball Team, Interviewed by: Taylor Uphus
ARTS & ENTERTAINMENT
Thanksgiving Film Recommendations!, Megan Napod
The Harder They Fall , Hannah Cruse
What is CATHARSIS?, Solana Campbell
NEWS
Andrews Autumn Conference on Science & Religion, Abigail Lee
AUSA Hosts Open Gym, Karenna Lee
Campus Concert Crawl, Abigail Lee
IDEAS
Hidden out of Season, Evin-Nazya Musgrove
Risk and Reward in Squid Game , Yoel Kim
The Necessity of Firearm Safety Education, Nathan Cheng
PULSE
Honors Testimony: Worship in the Church, Honors Student
Productivity... (and Pronouns ), T Bruggemann
Thanksgiving Traditions of Your Student Movement Editors, Alannah Tjhatra
THE LAST WORD
Thanksgiving Dinner and Communion, Alyssa Henriquezhttps://digitalcommons.andrews.edu/sm-106/1007/thumbnail.jp
High resolution hemodynamic profiling of murine arteriovenous fistula using magnetic resonance imaging and computational fluid dynamics
Robust estimation of bacterial cell count from optical density
Optical density (OD) is widely used to estimate the density of cells in liquid culture, but cannot be compared between instruments without a standardized calibration protocol and is challenging to relate to actual cell count. We address this with an interlaboratory study comparing three simple, low-cost, and highly accessible OD calibration protocols across 244 laboratories, applied to eight strains of constitutive GFP-expressing E. coli. Based on our results, we recommend calibrating OD to estimated cell count using serial dilution of silica microspheres, which produces highly precise calibration (95.5% of residuals <1.2-fold), is easily assessed for quality control, also assesses instrument effective linear range, and can be combined with fluorescence calibration to obtain units of Molecules of Equivalent Fluorescein (MEFL) per cell, allowing direct comparison and data fusion with flow cytometry measurements: in our study, fluorescence per cell measurements showed only a 1.07-fold mean difference between plate reader and flow cytometry data
Automated Navigation and Mobile Vehicle Control using Wireless Sensor Network Technology
This paper introduces a novel concept for automated navigation and control of a mobile platform. It utilizes an ad-hoc mobile wireless sensor network to provide navigational information to the mobile platform embedded control system. The embedded controller is realized with an ARM9 SOC based single board computer, with real time, multi-thread software implementation using a real time Linux operating system framwork. We have repeatedly tested the automated navigation and control concept on a wheel based mobile platform in an indoor environment, and found the performance meeting our original design goals
A single dose of K11777 protects chicken embryos in an <i>in vivo</i> model of toxoplasmosis.
<p>Fourteen day old chick eggs (N = 10/ treatment) were injected through the chorioallantoic vein with 10<sup>4</sup> RH tachyzoites in media alone (Control) or media containing K11777 for a final blood concentration of 20 uM). The Kaplan-Meier Survival curve of the chick embryos (N = 10 per group) showed that 100% of the chick embryos treated with a single dose of K11777 embryos survived until Day 6 vs. only 20% of the control embryos (p = 0.015 by Cox regression analysis).</p
Two key cathepsins, TgCPB and TgCPL, are targeted by the vinyl sulfone inhibitor K11777 in <i>in vitro</i> and <i>in vivo</i> models of toxoplasmosis - Fig 3
<p>(A) A single dose of K11777 reduces parasite load in the brain of chicken embryos. K11777 treated chicken embryos (N = 10) (final blood concentration 20 μM) showed a 3-log reduction in parasite burden in brain tissue as measured by quantitative PCR compared to chicken embryos injected with parasites in media alone (N = 10) (Control). Error bars reflect SEM. (B) A single dose of K11777 reduces parasite load in the liver of chick embryos. K11777 treated chicken embryos (final blood concentration 20 μM) showed a 4-log reduction in parasite burden in liver tissue as measured by quantitative PCR compared to chicken embryos injected with parasites in media alone (Control). Error bars reflect SEM.</p
Recommended from our members
A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease.
Novel coronavirus disease 2019 (COVID-19) is a highly infectious, rapidly spreading viral disease with an alarming case fatality rate up to 5%. The risk factors for severe presentations are concentrated in patients with chronic kidney disease, particularly patients with end-stage renal disease (ESRD) who are dialysis dependent. We report the first US case of a 56-year-old nondiabetic male with ESRD secondary to IgA nephropathy undergoing thrice-weekly maintenance hemodialysis for 3 years, who developed COVID-19 infection. He has hypertension controlled with angiotensin receptor blocker losartan 100 mg/day and coronary artery disease status-post stent placement. During the first 5 days of his febrile disease, he presented to an urgent care, 3 emergency rooms, 1 cardiology clinic, and 2 dialysis centers in California and Utah. During this interval, he reported nausea, vomiting, diarrhea, and low-grade fevers but was not suspected of COVID-19 infection until he developed respiratory symptoms and was admitted to the hospital. Imaging studies upon admission were consistent with bilateral interstitial pneumonia. He was placed in droplet-eye precautions while awaiting COVID-19 test results. Within the first 24 h, he deteriorated quickly and developed acute respiratory distress syndrome (ARDS), requiring intubation and increasing respiratory support. Losartan was withheld due to hypotension and septic shock. COVID-19 was reported positive on hospital day 3. He remained in critical condition being treated with hydroxychloroquine and tocilizumab in addition to the standard medical management for septic shock and ARDS. Our case is unique in its atypical initial presentation and highlights the importance of early testing
Two key cathepsins, TgCPB and TgCPL, are targeted by the vinyl sulfone inhibitor K11777 in <i>in vitro</i> and <i>in vivo</i> models of toxoplasmosis
<div><p>Although toxoplasmosis is one of the most common parasitic infections worldwide, therapeutic options remain limited. Cathepsins, proteases that play key roles in the pathogenesis of toxoplasmosis and many other protozoan infections, are important potential therapeutic targets. Because both TgCPB and TgCPL play a role in <i>T</i>. <i>gondii</i> invasion, we evaluated the efficacy of the potent, irreversible vinyl sulfone inhibitor, K11777 (<i>N-</i>methyl-piperazine-Phe-homoPhe-vinylsulfone-phenyl). The inhibitor’s toxicity and pharmacokinetic profile have been well-studied because of its <i>in vitro</i> and <i>in vivo</i> activity against a number of parasites. We found that it inhibited both TgCPB (EC50 = 114 nM) and TgCPL (EC50 = 71 nM) <i>in vitro</i>. K11777 also inhibited invasion of human fibroblasts by RH tachyzoites by 71% (p = 0.003) and intracellular replication by >99% (p<0.0001). <i>In vivo</i>, a single dose of K11777 led to 100% survival of chicken embryos in an model of acute toxoplasmosis (<i>p</i> = 0.015 Cox regression analysis). Therefore, K11777 shows promise as a novel therapeutic agent in the treatment of toxoplasmosis, and may prove to be a broadly effective anti-parasitic agent.</p></div